Literature DB >> 17652623

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

Yu Fang Wang1, Chen Chen Jiang, Kelly Anne Kiejda, Susan Gillespie, Xu Dong Zhang, Peter Hersey.   

Abstract

PURPOSE: Given that inhibitors of mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) are being introduced into treatment for melanoma, the present study was carried out to better understand the mechanism by which they may induce apoptosis of melanoma cells. EXPERIMENTAL
DESIGN: A panel of human melanoma cell lines and fresh melanoma isolates was assessed for their sensitivity to apoptosis induced by the MEK inhibitor U0126. The apoptotic pathways and regulatory mechanisms involved were examined by use of the inhibitor and small interfering RNA (siRNA) techniques.
RESULTS: Inhibition of MEK induced apoptosis in the majority of melanoma cell lines through a mitochondrial pathway that was associated with the activation of Bax and Bak, release of mitochondrial apoptogenic proteins, and activation of caspase-3. However, apoptosis was independent of caspases and instead was associated with mitochondrial release of AIF as shown by the inhibition of apoptosis when AIF was knocked down by siRNA. Inhibition of MEK resulted in the up-regulation of the BH3-only proteins PUMA and Bim and down-regulation of the antiapoptotic protein Mcl-1. These changes were critical for the induction of apoptosis by U0126 as siRNA knockdown of PUMA or Bim inhibited apoptosis, whereas siRNA knockdown of Mcl-1 increased apoptosis particularly in the apoptosis-resistant cell lines.
CONCLUSIONS: Apoptosis of melanoma cells induced by the inhibition of the MEK/ERK pathway is mediated by the up-regulation/activation of PUMA and Bim and down-regulation of Mcl-1. Release of AIF rather than the activation of caspases seems to be the mediator of apoptosis. Our results suggest that cotargeting Mcl-1 and the MEK/ERK pathway may further improve treatment results in melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652623     DOI: 10.1158/1078-0432.CCR-07-0665

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  92 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

2.  Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.

Authors:  M Corazzari; F Rapino; F Ciccosanti; P Giglio; M Antonioli; B Conti; G M Fimia; P E Lovat; M Piacentini
Journal:  Cell Death Differ       Date:  2014-11-07       Impact factor: 15.828

3.  17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Authors:  Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel-Johnson; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

4.  The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.

Authors:  Manali S Phadke; Patrizia Sini; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2015-04-14       Impact factor: 6.261

5.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

6.  The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.

Authors:  Rui Huang; Xue-Qin Chen; Ying Huang; Ni Chen; Hao Zeng
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

7.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

8.  BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Authors:  Heike Niessner; Tobias Sinnberg; Corinna Kosnopfel; Keiran S M Smalley; Daniela Beck; Christian Praetorius; Marion Mai; Stefan Beissert; Dagmar Kulms; Martin Schaller; Claus Garbe; Keith T Flaherty; Dana Westphal; Ines Wanke; Friedegund Meier
Journal:  Clin Cancer Res       Date:  2017-07-19       Impact factor: 12.531

Review 9.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

10.  Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.

Authors:  Kevin J Basile; Andrew E Aplin
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.